Device Trial Radar · NCT02478112
Use of a Biodegradable Balloon for the Treatment of Prostate Cancer by Intensity Modulated Radiotherapy (BioPro-RCMI)
Last checked: Nov 20, 2026Latest source record: Mar 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
24
Actual
Start
Nov 25, 2016
Primary completion
May 28, 2018
Study completion Sep 7, 2020
Sponsor
- Lead sponsor
- Centre Oscar LambretAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Aquilab SAS
- First posted
- Jun 23, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The benefit of dose escalation in radiotherapy (RT) for biochemical control of prostate cancer is a clearly established fact based on the results of different published prospective trials. This benefit, acquired with three-dimensional conformal radiation technique is counterbalanced by an increase in urinary and gastrointestinal toxicity. The joint progress of dose planning systems and multileaf collimators (MLC) technology have enabled the Intensity Modulated Radiation Therapy (IMRT). Recently the contribution of "spacers" positioned in the septum between the rectum and the prostate could improve the functional results of IMRT in terms of rectal toxicity. The aim of the investigators study is to assess the dosimetric gain from the contribution of the implantable BioProtect balloon on organs at risk.
Conditions
- Prostate Cancer
Interventions
Biodegradable balloon implantDevice
Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dosimetric gain from the contribution of the balloon on organs at riskTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Clinique Pasteur
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.